Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effect of Hypnosis on Blood Concentrations of Endocannabinoids

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03407937
Recruitment Status : Completed
First Posted : January 23, 2018
Last Update Posted : October 31, 2018
Sponsor:
Information provided by (Responsible Party):
Université de Sherbrooke

Brief Summary:
Introduction: Many interventions such as hypnosis, mindfulness meditation, conditioned pain modulation and placebos have been shown to effectively reduce pain both in the laboratory and in clinical settings. However, little is known about their neurophysiological mechanisms of action. Analgesia induced by these techniques is thought to be based on opioidergic and non-opioidergic mechanisms (potentially endocannabinoid mechanisms). Objective: Our main objective is to evaluate the effect of hypnosis, meditation, conditioned pain modulation and placebo on blood concentrations of endocannabinoids (anandamide, 2-arachidonylglycerol, N-palmitoyl-ethanolamine, N-oleoylethanolamide), endogenous opioids (β-endorphins, met / leu-enkephalins, and dynorphins) and norepinephrine in healthy adults. Methods: This study is based on a single-group pre-experimental research design in which two experimental sessions including hypnosis or meditation, conditioned pain modulation and placebo interventions will be completed by all participants. In order to have a better description of the sociodemographic and clinical characteristics of the sample, information will be collected by questionnaires or tests filled by participants at baseline, including: age, sex, language, culture, religion, salary, menstrual cycle of women, medication (if any), mood, anxiety, pain catastrophizing, mindfulness, hypnotic susceptibility, and DNA information. Outcome measures will be collected before, during and after each intervention. The primary outcome is plasma concentrations of endocannabinoids. Secondary measurements include plasma concentrations of endogenous opioids and norepinephrine; change in pain intensity during the thermal noxious stimuli; and autonomic nervous system variability (as measured by heart rate variability). Anticipated results: The investigators expect a positive relationship between the change in pain intensity (analgesia) induced by the interventions (hypnosis, meditation, conditioned pain modulation, and placebo) and the change (increase) in plasma concentrations of endocannabinoids, opioids, and norepinephrine in healthy adults. It is also believed that the interventions will influence heart rate variability. Moreover, it is expected that there will be a relationship between the efficiency of the analgesic intervention and some gene polymorphisms associated to pain modulation and endocannabinoids, opioids or norepinephrine in healthy individuals.

Condition or disease Intervention/treatment Phase
Hypnosis Endocannabinoids Analgesia Behavioral: Hypnosis Behavioral: Meditation Other: Conditioned pain modulation Drug: Placebo Oral Tablet Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Repeated measures on a single group of participants
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: The Role of the Endocannabinoids During the Analgesia Caused by Hypnosis and Meditation
Actual Study Start Date : November 14, 2017
Actual Primary Completion Date : September 1, 2018
Actual Study Completion Date : September 1, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Intervention
Receiving the conditioned pain modulation intervention during the first session and receiving the placebo and the hypnosis or meditation interventions during the second session.
Behavioral: Hypnosis
Hypnosis is a therapeutic method in which the experimenter or therapist make suggestions to individuals after they have undergone a hypnotic induction. This induction is a relaxation procedure designed to focus one's mind and to induce a hypnotic trance in individuals. The hypnotic trance consists in a state of deep absorption, concentration and altered sensations, cognitions and behaviors. Hypnosis can be used for pain control in experimental and clinical settings. In this study, standardized hypnosis including a relaxation technique for the hypnotic induction and a direct hypnotic analgesia technique for the hypnotic suggestions will be used.
Other Name: Hypnotic suggestions

Behavioral: Meditation
Meditation is a relaxation method that can be used to reduce pain symptoms and pain perception in clinical and experimental situations. In this study, a standardized mindfulness meditation session of 20 minutes will be used to induce a relaxation and an analgesic effect in participants. Mindfulness meditation is a practice intended to increase mindfulness and awareness of the self and the environment by techniques of controlled breathing, focus on neutral elements, and observation of one's thoughts and emotions without judgment.
Other Name: Mindfulness meditation

Other: Conditioned pain modulation
Conditioned pain modulation (CPM) is a pain inhibition mechanism that is used to assess endogenous analgesia capacity. The method to evaluate CPM in healthy individuals and patients with pain includes both a conditioning stimulus (a noxious stimulus that induces CPM) and a test stimulus (a noxious stimulus used to evaluate the analgesic response to the conditioning stimulus). In this study, the conditioning stimulus will be a cold pressor test (two-minutes immersion of one hand in ice water) and the test stimulus will be a two-minutes thermal noxious stimulus delivered by a contact thermode.
Other Names:
  • CPM
  • Pain modulation
  • Diffuse noxious inhibitory control
  • DNIC
  • Hetero-segmental counter-irritation

Drug: Placebo Oral Tablet
A placebo is a substance (or treatment) with no active therapeutic effect. The placebo effect (analgesia) in this study will be induced by the oral administration of one inert tablet (sugar pill). The tablet is a round, hard, white, flat-faced tablet with no active ingredient. The participant is told that the tablet is an active drug, more specifically an analgesic or a painkiller, that is used to achieve analgesia, relief from pain. This placebo condition is used to induce a diffuse analgesic effect in participants.
Other Names:
  • Placebo analgesia
  • Placebo effect
  • Placebo




Primary Outcome Measures :
  1. Change from baseline concentration of endocannabinoids at the end of the intervention [ Time Frame: Immediately before and after each intervention ]
    Concentrations (ng/ml) of endocannabinoids (anandamide, 2-arachidonylglycerol, N-palmitoyl-ethanolamine, N-oleoylethanolamide) will be measured in the plasma of participants


Secondary Outcome Measures :
  1. Change from baseline concentrations of opioids at the end of the intervention [ Time Frame: Immediately before and after each intervention ]
    Concentrations (ng/ml) of opioids (beta-endorphins, met/leu-enkephalins, and dynorphins) will be measured in the plasma of participants

  2. Change from baseline concentrations of norepinephrine at the end of the intervention [ Time Frame: Immediately before and after each intervention ]
    Concentrations (ng/ml) of norepinephrine will be measured in the plasma of participants

  3. Quantitative aspect of pain [ Time Frame: Immediately before and after each intervention ]
    Quantitative aspect of pain, or pain intensity, will be measured and averaged for the entire duration (two minutes) of the pain tests on a Computerized Visual Analog Scale (CoVAS). This CoVAS scale ranges from 0% to 100%. Higher values on this scale represent more intense pain.

  4. Measure of the autonomic nervous system [ Time Frame: Immediately before, during and immediately after each intervention ]
    This outcome will be measured by heart rate variability

  5. DNA in salivary sample [ Time Frame: Immediately after all the interventions have been completed, which will be during the second session after the pill has been ingested ]
    DNA polymorphisms potentially associated with analgesia, endocannabinoids, opioids or norepinephrine


Other Outcome Measures:
  1. Anxiety [ Time Frame: Immediately before each intervention ]
    This outcome will be measured on the State-Trait Anxiety Inventory (form Y)

  2. Mood [ Time Frame: Immediately after the consent form has been signed, before any intervention is performed ]
    This outcome will be measured by the Beck Depression Inventory

  3. Pain catastrophizing [ Time Frame: Immediately after the consent form has been signed, before any intervention is performed ]
    This outcome will be measured by the Pain Catastrophizing Scale (PCS). The PCS inquire participants to reflect on past painful experiences, and to indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain. Each item of the PCS is scored on a 5-point scale where 0 = not at all and 4 = all the time. PCS yields three subscale scores assessing rumination, magnification and helplessness. The PCS total score is computed by summing responses to all 13 items. The PCS yields a total score ranging from 0 to 52. Higher values on this scale represent a greater tendency of the subject to perceive pain negatively and to foresee the consequences of pain in a more catastrophic way.

  4. Hypnotic susceptibility [ Time Frame: Before the hypnosis intervention is performed, during the first session (immediately after the conditioned pain modulation intervention is completed) ]
    This outcome will be measured by the Stanford Hypnotic Susceptibility Scale: Form A (SHSS:A). This scale was developed to measure susceptibility to hypnosis with items increasing in difficulty. Following a standardized hypnotic induction, the hypnotized individual is given 12 suggestions. Each suggestion is scored on 1 (0 if failed and 1 if passed). SHSS:A yields a total score between 0 and 12. The higher the total score (on 12), the more responsive to hypnosis the subject is.

  5. Hypnotic depth [ Time Frame: Immediately after each hypnotic suggestions that will given during the Stanford Hypnotic Susceptibility Scale: Form A and during the hypnosis intervention ]
    This outcome will be measured by the Long Stanford Scale. Each item (i.e., hypnotic suggestion) is scored on 10 where 0 = wide awake, 1 = borderline, 2 = light, 5 = deep, 10 = very deep. Higher scores suggest greater hypnotic depth for the item (hypnotic suggestion).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Being an healthy adult aged 18-45 years old with no prior experience of hypnosis.

Exclusion Criteria:

  • Having difficulty understanding french language
  • Having a vulnerability to dissociative or psychotic episodes
  • Having a diagnosed medical condition or diagnosis of chronic pain leading to kidney, liver, dermatological, respiratory, hematological, immunological, cardiovascular, inflammatory, rheumatologic, endocrine, metabolic, neurological or psychiatric pathologies
  • Being pregnant or breast-feeding
  • Having a body mass index over 40
  • Using medication, recreational drugs or other agents that affect the central nervous system or the perception of pain (e.g., analgesics, opioids, antiepileptics, muscle relaxers)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03407937


Locations
Layout table for location information
Canada, Quebec
CRCHUS: Centre de recherche du centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada, J1H5N4
Sponsors and Collaborators
Université de Sherbrooke
Investigators
Layout table for investigator information
Principal Investigator: Serge Marchand, Ph.D. Université de Sherbrooke
Principal Investigator: Guillaume Leonard, Ph.D. Université de Sherbrooke

Layout table for additonal information
Responsible Party: Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT03407937     History of Changes
Other Study ID Numbers: 2017-1477
First Posted: January 23, 2018    Key Record Dates
Last Update Posted: October 31, 2018
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Université de Sherbrooke:
Placebo
Hypnosis
Meditation
Conditioned pain modulation
Endocannabinoids
Opioid peptides
Norepinephrine
Pain
Analgesia
Genes
Heart rate variability

Additional relevant MeSH terms:
Layout table for MeSH terms
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs